Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board.
Dr. Cecere is the McGill University Chief of Cardiac Surgery, Surgical Director of the Heart Failure and Heart Transplantation Program, and Director of the Mechanical Circulatory Support Program. He is also Associate Member of the McGill University Department of Mechanical Engineering, and a Director and Principal Investigator of the Research Institute of the MUHC Myocardial Regeneration Laboratory.
For over a decade, Dr. Cecere's lab has been investigating novel methods to strengthen the stem-cell induced regeneration of infarcted heart tissue. Dr. Cecere has utilized placenta-derived stem cells and investigated their regenerative potential in different animal models of myocardial infarction ("MI"). More recently, Dr. Cecere's lab is actively involved in a project to create a platform to generate patient-specific cardiomyocytes from the blood of patients with heart failure. In Dr. Cecere's recent project (under review, Journal of Tissue Engineering and Regenerative Medicine), the team encapsulated placenta derived stem cells in a hydrogel scaffold and implanted it in a rat MI model. The stem cell/scaffold composite enhanced several parameters of cardiac function, including ejection fraction and fractional shortening, while also reducing fibrosis and increasing angiogenesis. In fact, Dr. Cecere's lab recently published a systematic review and meta-analysis that demonstrated that stem cells combined with bioactive scaffolds provide enhanced tissue regeneration in animal models of MI, compared to stem cells injected alone. This study paves the way for future research and clinical trials, supporting the use of ACP-01-based bioactive scaffolds to improve the stem cell-induced repair after a MI.
"I have worked in the field of heart-based stem cell science for more than a decade, and I find ACP-01's unique properties, safety profile and statistically significant preliminary intramyocardial efficacy results to be very promising" said Dr. Cecere. I look forward to collaborating with management to create the best product to repair hearts before an infarct or following an infarct, and designing a clinical trial of ACP-01 that proves its efficacy" said Dr. Cecere.
"Hemostemix is delighted to welcome Dr. Cecere to our team. His appointment to the SAB is the first of many areas of collaboration. As one of Canada's most well-regarded stem cell focused heart transplant surgeons, Dr. Cecere and his team enable Hemostemix to fast-track product development and clinical trials. We very much look forward to his counsel and his teams' collaboration to trial ACP-01 based bioactive scaffolds to improve stem cell-induced repair of the heart," stated Thomas Smeenk, CEO.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit http://www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-FounderEM: tsmeenk@hemostemix.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the lead product ACP-01, future studies of ACP-01 in bioactive scaffolds to improve the stem cell-induced repair after an infarct, the company's Clinical Trial results, and the results of the retrospective study of ischemic and dilated cardiomyopathy, and the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137137
View original post here:
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board - Yahoo Finance
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 21st, 2024
- Harvard Stem Cell Institute (HSCI) - December 29th, 2023
- Stem cell - Wikipedia - December 29th, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Focus On Stem Cell Research | National Institute of Neurological ... - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of... - October 21st, 2022
- NIH Guidelines for Human Stem Cell Research - October 13th, 2022
- Ethics of Stem Cell Research - Blue Marble Space Institute of Science - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Stem Cell Therapy Market (2022-2029) Size Will Escalate Rapidly in the Near Future: Osiris Therapeutics, Molmed - Digital Journal - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research - October 13th, 2022
- Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector - ResearchAndMarkets.com -... - October 13th, 2022
- Nancy and Geoffrey Stack Family Foundation give $2 million to UCI Health - UCI News - October 4th, 2022
- Cell Isolation Market is expected to generate a revenue of USD 20.50 Billion by 2028, Globally, at 15.70% CAGR: Verified Market Research -... - September 25th, 2022
- Creating stem cells from minipigs offers promise for improved treatments - University of Wisconsin-Madison - September 16th, 2022
- Genomics study identifies unique set of proteins that restores hearing in zebrafish - National Institutes of Health (.gov) - September 16th, 2022
- Discovered Key Mechanisms to Improve Intestinal Regeneration and Alleviate the Side Effects of Radiotherapy - Imaging Technology News - September 16th, 2022
- Global Cell Expansion Market Size to Grow at a CAGR of 15% during the Forecast Period 2022-2027 - Digital Journal - September 16th, 2022
- The American Cancer Society Awards $2.1 Million to Montefiore Einstein Cancer Center to Support Cancer Research and Tackle Inequities - Yahoo Finance - September 16th, 2022
- Hair Restoration Market | Stem Cell hair Restoration and Low-level Laser Therapy (LLLT) segment are Expected to Witness Significant CAGR - MDC... - August 30th, 2022
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - August 5th, 2022
- 'Off the shelf' CAR T cells for cancer treatment? - Boston Children's Answers - Boston Children's Discoveries - August 5th, 2022
- Inflammation accelerates aging of the hematopoietic system - EurekAlert - August 5th, 2022
- New patent-pending method mass-produces antitumor cells to treat blood diseases and cancer - Purdue University - August 5th, 2022
- Cell Therapy Technologies Market worth $8.0 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - August 5th, 2022
- Twenty-Five Years After My House Call To Dolly: What Have We Learned About Cloning And How Did We Learn It? - Forbes - August 5th, 2022
- Tendon Stem Cell Therapy Market is Booming Worldwide with Strong Growth Prospects | Cellualar Dynamics, Cellectis, International Stem cell... - July 27th, 2022
- [Pangyo Bio & Medical] Theragen Bio discovers MAST4 Protein that Regulates Bone Cartilage Development For 'The First Time in The World' - Digital... - July 27th, 2022
- Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. - PR Newswire - July 27th, 2022
- Cryopreservation Equipment Market Report 2022-2028: Importance of Cryopreservation for Success of Cell-Based Therapies Presents Opportunities -... - July 27th, 2022
- Whitmer axes stem cell research, pregnancy center funding over abortion access concerns - MLive.com - July 19th, 2022
- Stem Cell - National Human Genome Research Institute Home - July 11th, 2022
- Induced Pluripotent Stem Cells (iPS) | UCLA Broad Stem Cell Center - July 11th, 2022
- Global 3D Cell Culture Market To Be Driven By Growing Impact Of Economy On Regenerative Medicine, Emerging Applications Of Gene Therapy During The... - July 11th, 2022
- New Combination Therapy Effective in Pediatric Leukemia - Technology Networks - June 22nd, 2022
- MIT Pioneers Technology To Grow Customizable Wood Products in the Lab With Little Waste - SciTechDaily - June 22nd, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 13th, 2022
- Scientists hope this injectable stem cell gel can repair heart attack damage and avoid transplants - Euronews - June 13th, 2022
- Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery - Business Wire - June 13th, 2022
- Fasting has pros and cons for muscle repair in mice - Futurity: Research News - June 13th, 2022
- First Clinical Trial of Transplanted 3D Ear Using Human Cells Proves Successful via 3DBio Therapeutics - Tech Times - June 4th, 2022
- Insights on the Dimethyl Sulfoxide (DMSO) Global Market to 2027 - Expanding Research and Development in Stem Cell Transplantation to Benefit Demand... - May 15th, 2022
- Scientists Rejuvenate Skin Cells by 30 Years, with Pioneering Potential - BioSpace - May 15th, 2022
- Global Flow Cytometry Market is expected to grow at a lucrative rate of 8% to reach $11 billion by 2026 A Robust Tool that Defines New Era for... - May 15th, 2022
- Global Mesenchymal Stem Cells Market Research Report to 2027 - Featuring Astellas Pharma, Axol Biosciences and BrainStorm Cell Therapeutics Among... - May 2nd, 2022
- Researchers share insights about the mechanisms of human embryo and create method to develop transcriptionally similar cells in tissue culture -... - May 2nd, 2022
- Flow Cytometry Market is Estimated Drive the Industry Growth Across World in Coming Year 2030 Queen Anne and Mangolia News - Queen Anne and Mangolia... - May 2nd, 2022
- Mini-heart chamber beats on its own just like the real thing - Futurity: Research News - May 2nd, 2022
- The Case Against Embryonic Stem Cell Research: An ... - April 6th, 2022
- Burst of accumulated zinc shows how the mineral boosts immune function, suggesting ways to improve health - EurekAlert - April 6th, 2022
- Hoyer Statement on the Retirement of Congressman Fred Upton - Majority Leader - April 6th, 2022
- 11 Stem Cell Research Pros and Cons Vittana.org - March 25th, 2022
- Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 - Times Higher Education - March 25th, 2022
- Google still has a problem with stem cell and unproven therapies - STAT - STAT - March 25th, 2022
- Medeze Named Frost & Sullivan's 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry - PR Newswire - March 25th, 2022
- Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry... - March 25th, 2022
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Future Business Opportunities 2022-2028 | Caladrius Biosciences, Vericel Corporation,... - March 25th, 2022
- Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data - Digital Journal - March 25th, 2022
- This Fancy AF Face Cream Was Invented by a Stem Cell Researcher - VICE - March 25th, 2022
- Freeze Thaw Chambers Market: The cryopreserved products segment is expected to drive the growth of the market - BioSpace - January 5th, 2022
- As Nave as They Get - Weizmann Wonder Wander - News, Features and Discoveries - Weizmann Institute of Science - January 5th, 2022
- Jake's mice: Searching for answers to the puzzle of autism - huntingdondailynews.com - January 5th, 2022
- Primary Cells, Stem Cells, Culture Media and Reagents Market to Witness Rapid Growth by 2029 | BrainStorm Cell Therapeutics Inc., Caladrius... - January 5th, 2022
- Gait Rehabilitation System Market: Rising incidence of various neurological disorders to drive the market - BioSpace - January 5th, 2022
- ARVO Foundation Announces 2022 Bert M. Glaser, MD Award for Innovative Retina Research Recipient - Newswise - January 5th, 2022
- Communication between cells plays a major role in deciding their fate - EurekAlert - December 24th, 2021
- The 10 Most Compelling Research Stories of 2021 - BioSpace - December 24th, 2021
- MRC Lead Apologizes Following Bullying Allegations - The Scientist - December 24th, 2021
- California Proposition 14, Stem Cell Research Institute ... - November 22nd, 2021
- Ethical Issues in Stem Cell Research - PubMed Central (PMC) - November 22nd, 2021
- Opinion | How Covid Raised the Stakes of the War Between Faith and Science - The New York Times - November 8th, 2021
- What is Stem Cell Research? | The Benefits of Stem Cell Research - October 5th, 2021
- An Overview of Stem Cell Research | The Center for Bioethics ... - October 5th, 2021
- Stem Cell Research: Uses, Types & Examples - October 5th, 2021
- Stem Cells | National Institutes of Health (NIH) - October 5th, 2021
- Stem cells: Therapy, controversy, and research - October 5th, 2021
- Focus On Stem Cell Research | National Institute of ... - October 5th, 2021